Latest autoimmune disease Stories
WASHINGTON, March 22, 2011 /PRNewswire-USNewswire/ -- A new report by the American Autoimmune Related Diseases Association (AARDA) examining the economic impact of autoimmune disease (AD) on Americans, their families and the United States was released today at a congressional briefing as part of AARDA's 2011 National Autoimmune Diseases Awareness Month activities. "The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending," presents an assessment of current...
Alliance For Lupus Research Commits $500,000 To Glean Genetic Basis For Lupus In African Americans And Other Ethnicities Powerful ImmunoChip Technology Expands Range of Testing NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more...
DETROIT, March 2, 2011 /PRNewswire-USNewswire/ -- The American Autoimmune Related Diseases Association Inc. (AARDA) has unveiled a multi-media public service/awareness campaign titled "We are 50 Million" to herald March 2011 as National Autoimmune Diseases Awareness Month. The campaign is designed to educate the general public about the magnitude of autoimmune disease and its impact on patients, families and the U.S. health care system. It spotlights the more than 100 known autoimmune...
HAYWARD, Calif., Feb. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Dr. Peter Thompson to its Board of Directors. Currently, Dr. Thompson is a venture partner with OrbiMed and is the founder and Managing Director of Strategicon Partners, an investment and management services company. In 2009, Dr....
New research finds pattern for detecting 'false-positive' ANA resultsThe presence of antinuclear antibodies (ANA) indicates the possibility of autoimmunity and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive" ANA test occurs in up to 13% of healthy individuals. In such cases the test detects the presence of autoantibodies that apparently are not associated with...
(Ivanhoe Newswire) "“ A new study provides insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE). The research shows an unexpected role for a key type of immune cell could provide a potential new therapeutic strategy for SLE and, possibly, other autoimmune diseases.SLE is a chronic systemic disease that can affect many regions of the body and, as a result, presents with diverse clinical symptoms. As is characteristic of other...
A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosusA new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE). The research, published by Cell Press in the December issue of the journal Immunity, reveals an unexpected role for a key type of immune cell and provides a potential new therapeutic strategy for SLE and,...
SAN DIEGO, Dec. 13, 2010 /PRNewswire/ -- Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer(TM) technology. TRL and Anaphore will generate novel trivalent proteins called Atrimers that can be programmed to bind to and activate or inhibit targets of interest. The partnership will focus on...
HAYWARD, Calif., Dec. 7, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that their product candidate varespladib (A-001) was awarded the 2010 European Society Pediatric Research Award at the Third Congress of the European Academy of Pediatric Societies 2010 in Copenhagen, Denmark where Dr. Daniele De Luca, MD, PhDst at the University Pope's Hospital and...
HAYWARD, Calif., Nov. 16, 2010 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has notified the US Food and Drug Administration (FDA) that the company has placed a voluntary hold on PEARL-SC, the Phase 2b study of A-623 for the treatment of Systemic Lupus Erythematosus (lupus), due to problems found with product vials. The company was recently...
